Live and Archived Fireside Chat Available at VirtualInvestorConferences.com

HOUSTON--(BUSINESS WIRE)--Feb. 28, 2024-- Kiromic BioPharma, Inc. (OTCQB: KRBP) ("Kiromic" or the "Company") announces that Chief Executive Officer Pietro Bersani, Chief Financial Officer Brian Hungerford and Chief Scientific Officer and Interim Operations Officer Leonardo Mirandola, Ph.D., will participate in the OTC Markets' Life Science Investor Forum in a Fireside Chat format, hosted by VirtualInvestorConferences.com, on March 7^th, 2024.

Date: March 7, 2024
Time: 11:00 a.m. Eastern time
Link: https://bit.ly/3OM3m93
Available for 1x1 meetings: March 7, 2024

This will be a live, interactive event where investors are invited to ask the company questions in real-time. An archived webcast will also be available after the event.

Investors are invited to pre-register and run a system check to expedite participation and receive event updates. For more information, please visit www.virtualinvestorconferences.com.

About Virtual Investor Conferences

Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors.

Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors.

About Kiromic BioPharma

Kiromic BioPharma, Inc. is a clinical-stage, fully integrated biotherapeutics company using its proprietary DIAMOND artificial intelligence (AI) 2.0 target discovery engine to develop and commercialize cell therapies focusing on immuno-oncology. Kiromic is developing a multi-indication allogeneic cell therapy platform that exploits the natural potency of Gamma Delta T-cells to target solid tumors. Kiromic's DIAMONDAI is where data science meets target identification to dramatically compress the years and hundreds of millions of dollars required to develop a live drug. The Company maintains offices in Houston, Texas. To learn more, visit www.kiromic.com and connect with us on Twitter and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240228415761/en/

Kiromic BioPharma
Linda Phelan Dyson, MPH
Global Head, Corporate Communications
ldyson@kiromic.com
281-468-7683

LHA Investor Relations
Tirth T. Patel
tpatel@lhai.com
212-201-6614

Virtual Investor Conferences
John M. Viglotti
SVP Corporate Services, Investor Access
OTC Markets Group
(212) 220-2221
johnv@otcmarkets.com

Source: Kiromic BioPharma, Inc.